Hypera S.A (HYPE3) - Total Liabilities
Based on the latest financial reports, Hypera S.A (HYPE3) has total liabilities worth R$15.38 Billion BRL (≈ $3.02 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Hypera S.A (HYPE3) equity growth momentum to track the company's year-over-year net asset growth rate.
Hypera S.A - Total Liabilities Trend (2005–2025)
This chart illustrates how Hypera S.A's total liabilities have evolved over time, based on quarterly financial data. See HYPE3 cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Hypera S.A Competitors by Total Liabilities
The table below lists competitors of Hypera S.A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Celldex Therapeutics Inc
NASDAQ:CLDX
|
USA | $55.03 Million |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC
|
USA | $895.31K |
|
Aura Minerals Inc
TO:ORA
|
Canada | CA$1.03 Billion |
|
Bufab Holding AB
ST:BUFAB
|
Sweden | Skr5.12 Billion |
|
ABL Bio Inc
KQ:298380
|
Korea | ₩114.79 Billion |
|
California Water Service Group
NYSE:CWT
|
USA | $3.82 Billion |
|
IHS Holding Ltd
NYSE:IHS
|
USA | $4.69 Billion |
|
Inner Mongolia First Machinery Group Co Ltd
SHG:600967
|
China | CN¥10.53 Billion |
Liability Composition Analysis (2005–2025)
This chart breaks down Hypera S.A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see HYPE3 company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.95 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.52 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hypera S.A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hypera S.A (2005–2025)
The table below shows the annual total liabilities of Hypera S.A from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | R$16.07 Billion ≈ $3.15 Billion |
+28.99% |
| 2024-12-31 | R$12.46 Billion ≈ $2.44 Billion |
-4.11% |
| 2023-12-31 | R$12.99 Billion ≈ $2.55 Billion |
-0.83% |
| 2022-12-31 | R$13.10 Billion ≈ $2.57 Billion |
+31.21% |
| 2021-12-31 | R$9.98 Billion ≈ $1.96 Billion |
+24.66% |
| 2020-12-31 | R$8.01 Billion ≈ $1.57 Billion |
+149.55% |
| 2019-12-31 | R$3.21 Billion ≈ $629.74 Million |
+40.19% |
| 2018-12-31 | R$2.29 Billion ≈ $449.20 Million |
-4.32% |
| 2017-12-31 | R$2.39 Billion ≈ $469.49 Million |
-10.57% |
| 2016-12-31 | R$2.68 Billion ≈ $524.99 Million |
-65.67% |
| 2015-12-31 | R$7.79 Billion ≈ $1.53 Billion |
+21.54% |
| 2014-12-31 | R$6.41 Billion ≈ $1.26 Billion |
+18.22% |
| 2013-12-31 | R$5.42 Billion ≈ $1.06 Billion |
-6.30% |
| 2012-12-31 | R$5.79 Billion ≈ $1.14 Billion |
-13.34% |
| 2011-12-31 | R$6.68 Billion ≈ $1.31 Billion |
+35.54% |
| 2010-12-31 | R$4.93 Billion ≈ $966.98 Million |
+84.16% |
| 2009-12-31 | R$2.68 Billion ≈ $525.06 Million |
+62.29% |
| 2008-12-31 | R$1.65 Billion ≈ $323.54 Million |
+29.03% |
| 2007-12-31 | R$1.28 Billion ≈ $250.75 Million |
+353.43% |
| 2006-12-31 | R$281.83 Million ≈ $55.30 Million |
+29.69% |
| 2005-12-31 | R$217.30 Million ≈ $42.64 Million |
-- |
About Hypera S.A
Hypera S.A. operates as a pharmaceutical company in Brazil. The company provides sweeteners products under the Adocyl, finn, and Zero-cal brands; analgesics and anti-inflammatories products under the Doril, Atroveran, Calminex, Alivium, Buscopan, Buscofem, geloll, Torsilax, Neosaldina, and naprohax brands; cold and flu remedies and decongestants products under BENEGRIO, Rinosoro, Blu, Neosoro, Co… Read more